Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Semarion
Cambridge, England, United Kingdomsemarion.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Semarion has developed and commercialized the SemaCyte® Microcarrier and Multiplexing Platforms, which enable miniaturized, high-throughput adherent cell assays. The technology allows for faster data generation—up to 18–20 times faster than traditional high-throughput screening—and requires up to 100 times fewer cells per screen. The platforms are being adopted by major pharma companies and CROs for drug discovery applications including antibody drug discovery and DNA damage repair assays. No clinical results as the company does not develop drugs.
- Modalities
- Device (cell assay microcarriers)Platform technology (enabling cell-based assays)Not directly therapeutic; enables research on all modalities using adherent cells
- Industry
- Non-Drug Biotech
02
Partnerships
o2h Discovery (CRO collaboration on DNA damage repair assays)
Beyond the preview
Go deeper on Semarion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Semarion.